Can postfertile life stages evolve as an anticancer mechanism?
نویسندگان
چکیده
منابع مشابه
How Fast Can We Evolve Something?
When applying a Genetic Algorithm to a new problem, how many generations should one reasonably expect to wait before reaching an acceptable solution? Using arguments based on information flow into the genepool, mediated by selection each generation, we present a rough and ready heuristic.
متن کاملMutually helping microbes can evolve by hitchhiking.
G roups of cooperating organisms can obtain advantages in foraging, predator defense, and environmental manipulation that are impossible for individuals to achieve on their own. Although classically studied in the context of animals, cooperation is now understood to be common among microscopic organisms, ranging from viruses (1) to bacteria (2) to unicellular eukaryotes (3). Every system of coo...
متن کاملPhytosterols as anticancer dietary components: evidence and mechanism of action.
Phytosterols (PS) or plant sterols are structurally similar to cholesterol. The most common PS are beta-sitosterol, campesterol and stigmasterol. Epidemiologic and experimental studies suggest that dietary PS may offer protection from the most common cancers in Western societies, such as colon, breast and prostate cancer. This review summarizes the findings of these studies and the possible mec...
متن کاملEndogenous anticancer mechanism: differentiation.
It has been recently shown that within heterogeneous tumor masses a small population of less differentiated transformed cells has the ability to self-renew and regenerate the bulk of the tumor. Their similarities with normal stem cells in terms of gene expression patterns, proliferative capacity and surface markers rendered them the name of cancer stem-like cells (CSC), and these are thought to...
متن کاملEribulin: rediscovering tubulin as an anticancer target.
Eribulin mesylate (E7389) is a synthetic analog of the marine macrolide halichondrin B, which acts as a novel microtubule modulator with a distinct mechanism of action. Two eribulin mesylate phase 1 studies exploring weekly and 3-weekly schedules are reported in this issue. These trials show linear pharmacokinetics, a toxicity profile consisting in neutropenia and fatigue, and early hints of an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: PLOS Biology
سال: 2019
ISSN: 1545-7885
DOI: 10.1371/journal.pbio.3000565